JP2022506898A - Nlrp活性に関連する状態を処置するための化合物及び組成物 - Google Patents

Nlrp活性に関連する状態を処置するための化合物及び組成物 Download PDF

Info

Publication number
JP2022506898A
JP2022506898A JP2021525010A JP2021525010A JP2022506898A JP 2022506898 A JP2022506898 A JP 2022506898A JP 2021525010 A JP2021525010 A JP 2021525010A JP 2021525010 A JP2021525010 A JP 2021525010A JP 2022506898 A JP2022506898 A JP 2022506898A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
compound according
ring
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506898A5 (cg-RX-API-DMAC7.html
Inventor
カッツ,ジェイソン
ロウシュ,ウィリアム
セイデル,ハンズ,マーティン
シェン,ドン-ミン
ヴェンカトラマン,シャンカー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022506898A publication Critical patent/JP2022506898A/ja
Publication of JP2022506898A5 publication Critical patent/JP2022506898A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021525010A 2018-11-13 2019-11-11 Nlrp活性に関連する状態を処置するための化合物及び組成物 Pending JP2022506898A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862760279P 2018-11-13 2018-11-13
US201862760244P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US62/760,279 2018-11-13
US62/760,248 2018-11-13
US62/760,244 2018-11-13
US201962795373P 2019-01-22 2019-01-22
US62/795,373 2019-01-22
US201962796361P 2019-01-24 2019-01-24
US201962796356P 2019-01-24 2019-01-24
US62/796,356 2019-01-24
US62/796,361 2019-01-24
PCT/US2019/060775 WO2020102100A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (2)

Publication Number Publication Date
JP2022506898A true JP2022506898A (ja) 2022-01-17
JP2022506898A5 JP2022506898A5 (cg-RX-API-DMAC7.html) 2022-11-21

Family

ID=68916531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525010A Pending JP2022506898A (ja) 2018-11-13 2019-11-11 Nlrp活性に関連する状態を処置するための化合物及び組成物

Country Status (6)

Country Link
US (1) US12134611B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880666B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022506898A (cg-RX-API-DMAC7.html)
CN (1) CN113166081A (cg-RX-API-DMAC7.html)
ES (1) ES2957692T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020102100A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN117185965B (zh) * 2023-09-18 2024-10-11 安徽金桐精细化学有限公司 一种磺酸基丙烯酸盐复配表面活性剂的制备方法
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026064385A1 (en) * 2024-09-18 2026-03-26 Ventus Therapeutics U.S., Inc. Oxadiazolone inhibitors of nlrp3 and uses thereof
CN119775202A (zh) * 2024-12-31 2025-04-08 河南旭瑞新材料科技有限公司 一种2-巯基烟酰甘氨酸的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510207A (ja) * 2015-02-16 2018-04-12 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
CA2085297A1 (en) 1991-12-20 1993-06-21 James Edward Ray Sulfonimidamides
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
PL344004A1 (en) 1998-05-05 2001-09-10 Hoffmann La Roche Pyrazole derivatives as p-38 map kinase inhibitors
CN1832928B (zh) 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
ITMI20131658A1 (it) 2013-10-08 2015-04-09 Getters Spa Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR102521955B1 (ko) 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
US11370763B2 (en) 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
PY1975819A (es) 2018-09-13 2020-04-09 Bayer Ag Derivados heterocíclicos como plaguicidas.-
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CN114008030A (zh) * 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510207A (ja) * 2015-02-16 2018-04-12 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用

Also Published As

Publication number Publication date
EP3880666B1 (en) 2023-06-28
WO2020102100A1 (en) 2020-05-22
WO2020102100A9 (en) 2022-01-06
US12134611B2 (en) 2024-11-05
US20230024859A1 (en) 2023-01-26
CN113166081A (zh) 2021-07-23
EP3880666A1 (en) 2021-09-22
ES2957692T3 (es) 2024-01-24

Similar Documents

Publication Publication Date Title
JP7654767B2 (ja) Nlrp活性に関連する状態を治療するための化合物及び組成物
JP7730759B2 (ja) Nlrp活性に関連する病態を治療するための化合物及び組成物
JP2022505525A (ja) Nlrp活性に関連する状態を治療するための化合物及び組成物
EP3880666B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
JP2021529187A (ja) Nlrpモジュレータ
JP2020528889A (ja) Nlrp活性に関連する状態を治療するための化合物及び組成物
JP2022507506A (ja) Nlrp活性に関連する状態を治療するための化合物及び組成物
JP2022518260A (ja) Nlrp活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
US20220227707A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
JP2022507505A (ja) Nlrp活性に関連する状態を治療するための化合物及び組成物
US20220387397A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
JP2021529186A (ja) Nlrp調節剤
JP2022506891A (ja) Nlrp活性に関連する状態を処置するための化合物及び組成物
HK40103462A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570B (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570A (en) Compounds and compositions for treating conditions associated with nlrp activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521